HC Wainwright & Co. Reiterates Buy on Revolution Medicines, Maintains $56 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Robert Burns has reiterated a Buy rating on Revolution Medicines (NASDAQ:RVMD) and maintained a $56 price target.
August 12, 2024 | 11:32 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst Robert Burns has reiterated a Buy rating on Revolution Medicines and maintained a $56 price target.
The reiteration of a Buy rating and the maintenance of a $56 price target by a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100